Xultophy

Before taking this medicine

Do not use Xultophy if you or anyone in your family has had medullary thyroid carcinoma (MTC), if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you are allergic to insulin degludec, liraglutide or any other ingredient. Do not use it during an episode of low blood sugar (hypoglycemia). Xultophy is not recommended for people with severe gastroparesis (severely delayed stomach emptying). During pregnancy, it should be used only if the potential benefit justifies the potential risk to the fetus. It must not be used with other GLP-1 receptor agonists. Conditions requiring caution include kidney or liver impairment, difficulty recognising low blood sugar, and a risk of low potassium. Low blood sugar and low potassium can be life-threatening. Changes to insulin treatment require close medical supervision and more frequent blood sugar checks. Closer monitoring may also be needed when other medicines, meal patterns or physical activity change. Other serious risks include inflammation of the pancreas, severe digestive side effects, dehydration-related kidney injury, gallbladder disease and severe allergic reactions. Stop using Xultophy if pancreatitis or an allergic reaction is suspected and seek medical care. Taking Xultophy with thiazolidinediones (TZDs) can cause fluid retention and heart failure. Tell your healthcare team before any planned surgery or procedure, as stomach contents entering the lungs during general anesthesia or deep sedation have been reported with GLP-1 receptor agonists. Never share a Xultophy pen, even if the needle is changed, and check the label before each injection to avoid medicine mix-ups.